In medical news:

The FDA approved KemPharm Inc.’s opioid painkiller Apadaz for the short-term management of acute pain. The company resubmitted the drug’s marketing application for review in September after appealing against a rejection by the drug regulator in 2016 on concerns of opioid abuse. KemPharm is in talks to market the drug without abuse deterrent labeling and close to the price of generics.

Read more via Reuters here.

Leave a Comment

Your email address will not be published. Required fields are marked *